This is a revised application from the William Dameshek Division of Hematology/Oncology at Tufts Medical Center for competitive renewal of our long-standing training grant, T32 CA09429, entitled """"""""Research Training in Oncology"""""""". The long-term objective of the application has not changed, which is to continue the training and mentoring of physicians in the Hematology/Oncology Division Fellowship Program in basic and translational cancer science, in order to prepare them for independent careers in academic hematology/oncology. The program is based in the Division of Hematology/Oncology at Tufts Medical Center (Tufts MC), the principal teaching hospital for Tufts University School of Medicine (TUSM). The training program is a highly structured research experience that is centered around laboratory investigation within the research group of a faculty mentor. The laboratory component is complimented by formal coursework, other didactic training, and participation in seminars, workshops, and meetings. The progress of each trainee is closely monitored by a research committee. The Program currently has 26 research faculty mentors drawn from members of the Division and from other clinical and basic science departments at Tufts MC and TUSM, a significant increase from 19 Program faculty in the last competitive renewal in 2002. This reflects a new emphasis on cancer in the strategic plans of Tufts MC and TUSM, leading to the establishment of the Molecular Oncology Research Institute, and a major institutional effort to obtain National Cancer Institute Comprehensive Cancer Center designation for the Tufts Medical Center Cancer Center. The Program faculty mentors represent a major strength of the application, and are carefully selected on the basis of their training record and for their specific research interests in neoplasia, which span the spectrum from oncogenes and tumor suppressors, signal transduction, cell cycle regulation and apoptosis, angiogenesis and metastasis, animal models of hematologic malignancies and solid tumors, and preclinical testing of molecularly targeted cancer therapeutics. This training Program has been highly successful in preparing our fellows for careers in academic oncology. Former trainees now head major departments in academia and in NCI designated cancer centers, are on faculty at academic institutions in the US and elsewhere, and hold senior management positions in the oncology pharmaceutical field.
The treatment of cancer has been revolutionized over the past ten years through the development of drugs that specifically target cancer cells. The United States has a great need for cancer doctors who work at the interface between cancer patients and experimental treatments, and who can discover and apply the next generation of therapies. This grant application will support the training of such physicians at Tufts Medical Center, continuing a program that has generated leaders in this field for more than a quarter century.
|Shah, Gunjan L; Winn, Aaron; Lin, Pei-Jung et al. (2016) Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. Bone Marrow Res 2016:3645623|
|Xu, Kun; Tian, Xuejun; Oh, Sun Y et al. (2016) The fibroblast Tiam1-osteopontin pathway modulates breast cancer invasion and metastasis. Breast Cancer Res 18:14|
|Buchsbaum, Rachel J; Oh, Sun Young (2016) Breast Cancer-Associated Fibroblasts: Where We Are and Where We Need to Go. Cancers (Basel) 8:|
|Winn, Aaron N; Shah, Gunjan L; Cohen, Joshua T et al. (2015) The real world effectiveness of hematopoietic transplant among elderly individuals with multiple myeloma. J Natl Cancer Inst 107:|
|Saret, Cayla J; Winn, Aaron N; Shah, Gunjan et al. (2015) Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. Blood 125:1866-9|
|Shah, Gunjan L; Winn, Aaron N; Lin, Pei-Jung et al. (2015) Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results-Medicare Database. Biol Blood Marrow Transplant 21:1823-9|
|Shah, Gunjan L; Rosenberg, Aaron S; Jarboe, Jamie et al. (2014) Incidence and evaluation of incidental abnormal bone marrow signal on magnetic resonance imaging. ScientificWorldJournal 2014:380814|
|Shah, Gunjan; Yamin, Hanah; Smith, Hedy (2013) Mitomycin-C-Induced TTP/HUS Treated Successfully with Rituximab: Case Report and Review of the Literature. Case Rep Hematol 2013:130978|
|Kaimal, Rajani; Aljumaily, Raid; Tressel, Sarah L et al. (2013) Selective blockade of matrix metalloprotease-14 with a monoclonal antibody abrogates invasion, angiogenesis, and tumor growth in ovarian cancer. Cancer Res 73:2457-2467|
|Ahmed, Wesam; Van Etten, Richard A (2013) Signal transduction in the chronic leukemias: implications for targeted therapies. Curr Hematol Malig Rep 8:71-80|
Showing the most recent 10 out of 34 publications